This inventor holds 2 USPTO granted patents. Top assignee: Glaxosmithkline Biologicals Sa. Active years: 2014-2023.
Company Filing History:
Years Active: 2014-2023
Title: Martine Harvey: Innovator in Vaccine Development
Introduction
Martine Harvey is a notable inventor based in Laval, Canada. He has made significant contributions to the field of vaccine development, particularly in relation to the Chikungunya virus. With a total of 2 patents, his work has the potential to impact public health positively.
Latest Patents
One of Martine Harvey's latest patents is focused on Chikungunya virus antigen constructs. This invention provides adenoviral vectors that comprise transgenes encoding Chikungunya virus antigens. These vectors can be utilized to produce vaccines aimed at the prophylaxis, amelioration, and treatment of diseases caused by Chikungunya virus infections. Another significant patent is related to CASB7439 constructs. This disclosure pertains to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, along with methods for utilizing these compounds effectively.
Career Highlights
Martine Harvey is currently associated with GlaxoSmithKline Biologicals SA, where he continues to advance his research and innovations in vaccine technology. His work is crucial in the ongoing efforts to combat viral infections and improve public health outcomes.
Collaborations
Martine collaborates with talented individuals in his field, including Benjamin Wizel and Lucile Warter, who contribute to the innovative environment at GlaxoSmithKline Biologicals SA.
Conclusion
Martine Harvey's contributions to vaccine development through his patents and collaborations highlight his role as an influential inventor in the field. His work promises to enhance the effectiveness of vaccines and improve health outcomes for those affected by viral infections.